“The Global Diabetes Devices Market is expected to grow at a CAGR of 5.5% during the forecasting period (2021-2028).”
The Diabetes Devices market is growing due to rising incidence rate of diabetes globally. According to the World Health Organization data (2018), the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. The global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. Diabetes prevalence has been rising more rapidly in middle- and low-income countries. In 2016, an estimated 1.6 million deaths were directly caused by diabetes. Another 2.2 million deaths were attributable to high blood glucose in 2012. Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO estimates that diabetes was the seventh leading cause of death in 2016.
In addition, with rising improvement in technology, there are several advanced diabetes devices introduced in the market which are driving the growth of the diabetes devices market. Earlier, the blood glucose concentration was monitored using disposable biosensors, but later on, many alternative methods were developed for continuous glucose monitoring. These include devices which are skin wearable, having a small needle with a sensor to check glucose in interstitial fluid, etc. Recently, the technology expanded to hybrid devices which can monitor glucose and deliver insulin accordingly. The idea of automated “closed loop” systems for pairing CGM (Continuous Glucose Monitoring) devices and insulin pumps are considered for diabetes management as a next level. Companies have come forth with various technology and plans for diabetes management to launch in 2019 including CGM and applications. For instance, in February 2019, Tandem Diabetes Care received the Food and Drug Administration (FDA) approval for slim X2 insulin pump with interoperable technology, the first of the Alternate Controller Enabled Infusion Pumps (ACE pumps), which are devices intended for infusion of drugs into a patient.
Download free sample: https://www.datamintelligence.com/download-sample/diabetes-devices-market
By Product Type
Glucose Monitoring Devices
Insulin Delivery Devices
By Distribution Network
Middle East & Africa
North America holds the dominant market share for Diabetes Devices in 2018, and is expected to maintain the growth over the forecast period, increasing prevalence of diabetes which is caused mainly due to urbanization and sedentary lifestyles. The United States is one of the top five countries with the highest diabetic population. The country has close to 100 million adults, diabetic and pre-diabetic. According to the Centers for Disease Control and Prevention (CDC), more than 30 million people in the United States have diabetes and more than 84 million US adults (over a third), have pre-diabetes. Diabetes is the 7th leading cause of death in the United States. Type 2 diabetes accounts for about 90% to 95% of all diagnosed cases of diabetes; type 1 diabetes accounts for about 5%. The market growth of diabetic devices is directly proportional to the increasing diabetic population in the country. In the last 20 years, the number of adults diagnosed with diabetes has more than doubled as the American population has aged and become more overweight or obese. In the United States, 30% of the population is living with obesity, 7.5% of those have diabetes, and this percentage is expected to increase further during the forecast period (2021-2028).
Some of the major manufacturers in the diabetes devices market are: Medtronic Plc, Sanofi S.A., Eli Lilly, Abbott Laboratories, Novo Nordisk, F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, Johnson & Johnson, Insulet Corp., among others.
The key players are adopting various growth strategies such as new product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the diabetes devices market globally. For instance,
In June 2019, Medtronic and Tidepool signed a partnership to create an interoperable automated insulin pump system. Medtronic plans to develop a Bluetooth-enabled MiniMed pump that would be compatible with Tidepool Loop, an open-source, automated insulin delivery app for iPhone and Apple Watch, which is currently in development.